Literature DB >> 15845858

Variability of CYP3A7 expression in human fetal liver.

J Steven Leeder1, Roger Gaedigk, Kenda A Marcucci, Andrea Gaedigk, Carrie A Vyhlidal, Bradley P Schindel, Robin E Pearce.   

Abstract

Fetal liver CYP3A7 plays an important role in placental estriol synthesis during pregnancy, yet little is known concerning the extent or consequences of variability in expression. The purpose of this investigation was to characterize the variability in CYP3A7 expression using several phenotypic measures in a panel of 54 fetal livers ranging in age from 76 days to 32 weeks gestation. CYP3A7 mRNA expression was measured using quantitative polymerase chain reaction, whereas immunoreactive CYP3A7 was determined using an affinity-purified antipeptide antibody. Variability in catalytic activity was evaluated using testosterone and dehydroepiandrosterone (DHEA) as substrates. Across the entire panel, CYP3A7 was the most abundant CYP3A mRNA species present and varied 634-fold from 151 to 95,700 transcripts/ng total RNA, corrected for 18S ribosomal RNA. CYP3A4 expression was minimal based on mRNA expression (1000-fold lower than CYP3A7) and the ratio of testosterone 2alpha- (T2alphaH) to 6beta- (T6betaH) hydroxylation. T2alphaH and T6betaH were highly correlated (r(2) = 0.859), and the correlation increased (r(2) = 0.974) in livers with CYP3A5*3/*3 genotypes implying that the same enzyme (CYP3A7) generated both products. Overall, T2alphaH and DHEA16alphaH activities varied 175- and 250-fold, respectively. A subset of five samples had extremely low mRNA, protein, and catalytic activity, possibly due to pathology affecting fetal viability (anencephaly, porencephaly). In the remaining samples, T2alphaH activity varied 6.7-fold (358 +/- 142, range 97 to 643 pmol/min/mg) and DHEA16alphaH activity varied 6.2-fold (8.07 +/- 2.87, range 2.41 to 14.9 nmol/min/mg). Observed variability in CYP3A7 activity was not related to CYP3A7*2, and alternative regulatory mechanisms require further investigation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15845858     DOI: 10.1124/jpet.105.086504

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  45 in total

Review 1.  Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy.

Authors:  Magnus Ingelman-Sundberg; Cristina Rodriguez-Antona
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-08-29       Impact factor: 6.237

2.  Meconium Atazanavir Concentrations and Early Language Outcomes in HIV-Exposed Uninfected Infants With Prenatal Atazanavir Exposure.

Authors:  Sarah K Himes; Yanling Huo; George K Siberry; Paige L Williams; Mabel L Rice; Patricia A Sirois; Toni Frederick; Rohan Hazra; Marilyn A Huestis
Journal:  J Acquir Immune Defic Syndr       Date:  2015-06-01       Impact factor: 3.731

3.  Identification of CYP3A7 for glyburide metabolism in human fetal livers.

Authors:  Diana L Shuster; Linda J Risler; Bhagwat Prasad; Justina C Calamia; Jenna L Voellinger; Edward J Kelly; Jashvant D Unadkat; Mary F Hebert; Danny D Shen; Kenneth E Thummel; Qingcheng Mao
Journal:  Biochem Pharmacol       Date:  2014-10-22       Impact factor: 5.858

4.  The impact of drug metabolizing enzyme polymorphisms on outcomes after antenatal corticosteroid use.

Authors:  David M Haas; Amalia S Lehmann; Todd Skaar; Santosh Philips; Catherine L McCormick; Kyle Beagle; Scott J Hebbring; Jessica Dantzer; Lang Li; Jeesun Jung
Journal:  Am J Obstet Gynecol       Date:  2012-02-28       Impact factor: 8.661

5.  Ontogeny of novel cytochrome P450 gene isoforms during postnatal liver maturation in mice.

Authors:  Julia Yue Cui; Helen J Renaud; Curtis D Klaassen
Journal:  Drug Metab Dispos       Date:  2012-03-23       Impact factor: 3.922

6.  Fluticasone propionate pharmacogenetics: CYP3A4*22 polymorphism and pediatric asthma control.

Authors:  Chris Stockmann; Bernhard Fassl; Roger Gaedigk; Flory Nkoy; Derek A Uchida; Steven Monson; Christopher A Reilly; J Steven Leeder; Garold S Yost; Robert M Ward
Journal:  J Pediatr       Date:  2013-01-03       Impact factor: 4.406

7.  The revised human liver cytochrome P450 "Pie": absolute protein quantification of CYP4F and CYP3A enzymes using targeted quantitative proteomics.

Authors:  Scott Michaels; Michael Zhuo Wang
Journal:  Drug Metab Dispos       Date:  2014-05-09       Impact factor: 3.922

8.  Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin.

Authors:  Dongfang Yang; Robin E Pearce; Xiliang Wang; Roger Gaedigk; Yu-Jui Yvonne Wan; Bingfang Yan
Journal:  Biochem Pharmacol       Date:  2008-10-15       Impact factor: 5.858

9.  Dynamic patterns of histone methylation are associated with ontogenic expression of the Cyp3a genes during mouse liver maturation.

Authors:  Ye Li; Yue Cui; Steven N Hart; Curtis D Klaassen; Xiao-bo Zhong
Journal:  Mol Pharmacol       Date:  2009-02-02       Impact factor: 4.436

10.  Molecular population genetics of human CYP3A locus: signatures of positive selection and implications for evolutionary environmental medicine.

Authors:  Xiaoping Chen; Haijian Wang; Gangqiao Zhou; Xiumei Zhang; Xiaojia Dong; Lianteng Zhi; Li Jin; Fuchu He
Journal:  Environ Health Perspect       Date:  2009-06-18       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.